Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the worldwide biotechnology,
biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage
industries, today announced that its pending merger partner Cannaworx, Inc.
will be launching its patented and proprietary immune booster supplement by
mid-July 2020. According to the update, the company believes that post-launch,
this product could be one of the very few, and perhaps the only, OTC (over the
counter), FDA registered, hemp-containing supplements with an immune booster
claim. “To further enhance the immune boosting effect, we added hemp seed oil
(no THC) to our patented formulation. Hemp seed oil is rich in essential fatty
acids (e.g., omega-6 and omega-3) and antioxidants that may help fight
inflammation, cancer, diabetes, and heart disease,” Dr. Bobby Ghalili,
co-founder and president of Cannaworx, stated in the news release. “Omega-3 is
also thought to have a positive impact on the bowel microbiome as a prebiotic,
providing further support to the immune system. The manufacturing process of
the patented 44 amino acid fragment formulation is highly proprietary,
protected, and would be nearly impossible to imitate.”
To view the full press release, visit http://ibn.fm/nqpvZ
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique properties
of both constant (i.e., static) and alternating (i.e., pressure-cycling
technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil and plant biology, forensics and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired, patented technology from BaroFold Inc. (the “BaroFold”
technology) to allow entry into the biopharma contract services sector, and (2)
the use of its recently patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and (ii) prepare
higher-quality, homogenized, extended shelf-life or room-temperature, stable,
low-acid liquid foods that cannot be effectively preserved using existing
nonthermal technologies. For more information, visit the company’s website
at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
